Cargando…

Identifying hepatocellular carcinoma patients with survival benefits from surgery combined with chemotherapy: based on machine learning model

BACKGROUND: Hepatocellular carcinoma (HCC) is still fatal even after surgical resection. The purpose of this study was to analyze the prognostic factors of 5-year survival rate and to establish a model to identify HCC patients with gain of surgery combined with chemotherapy. METHODS: All patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Jie, Gong, Ni, Li, Dan, Deng, Youyuan, Chen, Jiawei, Luo, Dingan, Zhou, Wei, Xu, Ke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714169/
https://www.ncbi.nlm.nih.gov/pubmed/36451200
http://dx.doi.org/10.1186/s12957-022-02837-2
_version_ 1784842164721680384
author Hu, Jie
Gong, Ni
Li, Dan
Deng, Youyuan
Chen, Jiawei
Luo, Dingan
Zhou, Wei
Xu, Ke
author_facet Hu, Jie
Gong, Ni
Li, Dan
Deng, Youyuan
Chen, Jiawei
Luo, Dingan
Zhou, Wei
Xu, Ke
author_sort Hu, Jie
collection PubMed
description BACKGROUND: Hepatocellular carcinoma (HCC) is still fatal even after surgical resection. The purpose of this study was to analyze the prognostic factors of 5-year survival rate and to establish a model to identify HCC patients with gain of surgery combined with chemotherapy. METHODS: All patients with HCC after surgery from January 2010 to December 2015 were selected from the Surveillance, Epidemiology, and End Results (SEER) database. Univariate and multivariate logistic analysis were used to analyze the prognostic factors of patients, and the risk prediction model of 5-year survival rate of HCC patients was established by classical decision tree method. Propensity score matching was used to eliminate the confounding factors of whether to receive chemotherapy in high-risk group or low-risk group. RESULTS: One-thousand six-hundred twenty-five eligible HCC patients were included in the study. Marital status, α-fetoprotein (AFP), vascular infiltration, tumor size, number of lesions, and grade were independent prognostic factors affecting the 5-year survival rate of HCC patients. The area under the curve of the 5-year survival risk prediction model constructed from the above variables was 0.76, and the classification accuracy, precision, recall, and F1 scores were 0.752, 0.83, 0.842, and 0.836, respectively. High-risk patients classified according to the prediction model had better 5-year survival rate after chemotherapy, while there was no difference in 5-year survival rate between patients receiving chemotherapy and patients not receiving chemotherapy in the low-risk group. CONCLUSIONS: The 5-year survival risk prediction model constructed in this study provides accurate survival prediction information. The high-risk patients determined according to the prediction model may benefit from the 5-year survival rate after combined chemotherapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12957-022-02837-2.
format Online
Article
Text
id pubmed-9714169
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97141692022-12-02 Identifying hepatocellular carcinoma patients with survival benefits from surgery combined with chemotherapy: based on machine learning model Hu, Jie Gong, Ni Li, Dan Deng, Youyuan Chen, Jiawei Luo, Dingan Zhou, Wei Xu, Ke World J Surg Oncol Research BACKGROUND: Hepatocellular carcinoma (HCC) is still fatal even after surgical resection. The purpose of this study was to analyze the prognostic factors of 5-year survival rate and to establish a model to identify HCC patients with gain of surgery combined with chemotherapy. METHODS: All patients with HCC after surgery from January 2010 to December 2015 were selected from the Surveillance, Epidemiology, and End Results (SEER) database. Univariate and multivariate logistic analysis were used to analyze the prognostic factors of patients, and the risk prediction model of 5-year survival rate of HCC patients was established by classical decision tree method. Propensity score matching was used to eliminate the confounding factors of whether to receive chemotherapy in high-risk group or low-risk group. RESULTS: One-thousand six-hundred twenty-five eligible HCC patients were included in the study. Marital status, α-fetoprotein (AFP), vascular infiltration, tumor size, number of lesions, and grade were independent prognostic factors affecting the 5-year survival rate of HCC patients. The area under the curve of the 5-year survival risk prediction model constructed from the above variables was 0.76, and the classification accuracy, precision, recall, and F1 scores were 0.752, 0.83, 0.842, and 0.836, respectively. High-risk patients classified according to the prediction model had better 5-year survival rate after chemotherapy, while there was no difference in 5-year survival rate between patients receiving chemotherapy and patients not receiving chemotherapy in the low-risk group. CONCLUSIONS: The 5-year survival risk prediction model constructed in this study provides accurate survival prediction information. The high-risk patients determined according to the prediction model may benefit from the 5-year survival rate after combined chemotherapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12957-022-02837-2. BioMed Central 2022-12-01 /pmc/articles/PMC9714169/ /pubmed/36451200 http://dx.doi.org/10.1186/s12957-022-02837-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Hu, Jie
Gong, Ni
Li, Dan
Deng, Youyuan
Chen, Jiawei
Luo, Dingan
Zhou, Wei
Xu, Ke
Identifying hepatocellular carcinoma patients with survival benefits from surgery combined with chemotherapy: based on machine learning model
title Identifying hepatocellular carcinoma patients with survival benefits from surgery combined with chemotherapy: based on machine learning model
title_full Identifying hepatocellular carcinoma patients with survival benefits from surgery combined with chemotherapy: based on machine learning model
title_fullStr Identifying hepatocellular carcinoma patients with survival benefits from surgery combined with chemotherapy: based on machine learning model
title_full_unstemmed Identifying hepatocellular carcinoma patients with survival benefits from surgery combined with chemotherapy: based on machine learning model
title_short Identifying hepatocellular carcinoma patients with survival benefits from surgery combined with chemotherapy: based on machine learning model
title_sort identifying hepatocellular carcinoma patients with survival benefits from surgery combined with chemotherapy: based on machine learning model
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714169/
https://www.ncbi.nlm.nih.gov/pubmed/36451200
http://dx.doi.org/10.1186/s12957-022-02837-2
work_keys_str_mv AT hujie identifyinghepatocellularcarcinomapatientswithsurvivalbenefitsfromsurgerycombinedwithchemotherapybasedonmachinelearningmodel
AT gongni identifyinghepatocellularcarcinomapatientswithsurvivalbenefitsfromsurgerycombinedwithchemotherapybasedonmachinelearningmodel
AT lidan identifyinghepatocellularcarcinomapatientswithsurvivalbenefitsfromsurgerycombinedwithchemotherapybasedonmachinelearningmodel
AT dengyouyuan identifyinghepatocellularcarcinomapatientswithsurvivalbenefitsfromsurgerycombinedwithchemotherapybasedonmachinelearningmodel
AT chenjiawei identifyinghepatocellularcarcinomapatientswithsurvivalbenefitsfromsurgerycombinedwithchemotherapybasedonmachinelearningmodel
AT luodingan identifyinghepatocellularcarcinomapatientswithsurvivalbenefitsfromsurgerycombinedwithchemotherapybasedonmachinelearningmodel
AT zhouwei identifyinghepatocellularcarcinomapatientswithsurvivalbenefitsfromsurgerycombinedwithchemotherapybasedonmachinelearningmodel
AT xuke identifyinghepatocellularcarcinomapatientswithsurvivalbenefitsfromsurgerycombinedwithchemotherapybasedonmachinelearningmodel